PERBEDAAN TITER ANTIBODI COVID-19 PADA KELOMPOK SETELAH VAKSIN KE DUA SINOVAC DAN VAKSIN KE TIGA MODERNA KARYAWAN PRODIA YOGYAKARTA

Yann, Tri Undari (2022) PERBEDAAN TITER ANTIBODI COVID-19 PADA KELOMPOK SETELAH VAKSIN KE DUA SINOVAC DAN VAKSIN KE TIGA MODERNA KARYAWAN PRODIA YOGYAKARTA. Other thesis, Sekolah Tinggi Ilmu Kesehatan Nasional.

	Text Fulltext Yann Tri Undari.pdf Restricted to Repository staff only Download (1MB)
	Text Intisari&Abstract.pdf Download (35kB)

Abstract

Vaccines are biological products that contain antigens which, when given to a person, can cause active specific immunity against a particular disease. The Sinovac vaccine was created in China with the inactivated virus method, which does not contain live virus because the virus has been killed. The Moderna vaccine was created on an mRNA platform in the United States made from the COVID-19 protein. Moderna vaccine is a type of mRNA (messenger RNA) vaccine. The purpose of this study was to determine the difference in antibody titer levels of COVID-19 in the groups after the second Sinovac vaccine and after the third Moderna vaccine, Prodia Yogyakarta employees. This research design is included in the type of quantitative research. The research design used in this study was analytical observational with a cross sectional approach. This research was carried out on Prodia employees after the third Moderna vaccine was drawn for approximately 1-2 months and then a Quantitative Anti-SARS CoV-2 examination was carried out. Based on the results of the Wilcoxon signed test, the Z value is -4.937 and the asymp sig value. (2-tailed) 0.000 is smaller than the 5% alpha level (0.05) so it rejects H0, so the conclusion is that there is a difference in Covid-19 antibody titers after the second Sinovac vaccine and the third Moderna, Prodia Yogyakarta employees.

Actions (login required)

View Item